Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Case into Six

10 September. The Athletics Integrity Unit statement issued on Thursday carries a single date, and it is doing double duty: the start of the provisional suspension and the start of a six-year ban. Ruti Aga, Ethiopia, marathon, age 32. Add six years and the return age is 38. In the depth of Ethiopian women's marathon running, a 38-year-old with a doping file on her name does not reach the selection table. That is where the real size of the sanction is decided, not in the wording of the release. Knowing the ban is six years is not enough. The question is how six was assembled. Two years for the presence violation found in a sample taken after a half marathon in China in March. Four years for tampering established during the investigation of the same case. Two and four, six. I ran the arithmetic twice because I did not believe the first answer. Aga is not a new name to anyone keeping road-racing score sheets. The 2026 Tokyo Marathon title is hers, along with three second-place finishes at World Marathon Majors. The source does not state her personal best; my old notes carry a 2:18 to 2:20 class, but that is my record, not the AIU's, and I will not use it here as a verified figure. What is verified is thin: a half marathon in China in March, which she won. No time, no splits, no field quality, not even the year. An AIU sample at a half marathon exists only if the race holds World Athletics Label status and an international elite field. That is my inference, not the statement's, and I will label it as such. What matters technically is this: the in-competition testing window for a road race opens at 23:59 the day before the race. An injection given days earlier can therefore be caught. The entire case turns on that window, and the media coverage turned it on something else. One correction belongs here, and this piece will carry only one. Reports called methylprednisolone a prohibited steroid and said WADA classes it as performance enhancing. Both are imprecise. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid, class S1. And the S9 condition is explicit: prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely legal. The consequence is that this was never a substance case. It was a route-and-timing case. That is precisely where a defence existed: with genuine medical records, the argument would have been about when the injection was given and why residue remained at the sample, and the sanction could have fallen below two years or ended as a reprimand. The window was closed not by the drug but by the paper. The arithmetic confirms it. Two years for presence is the sanction band where a panel does not find proven intent. Four years for tampering is the Code's standard penalty. Six in total. Two things follow. The panel declined the no-significant-fault mitigation that would have cut the presence sanction. And it treated the tampering as fully culpable. There is a paradox the statement does not record: forged documentation is itself circumstantial evidence of concealment, yet it did not escalate the presence sanction. It was billed to a separate account. The forged prescription failed in three places, and the failures are independent. The clinic named on it did not exist. The person who wrote it was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned the claim. The book nobody wanted was wrong in a way that told me everything. A figure is only as honest as the hand that typed it; here the hand was not registered at all. What the statement omits should also be on the record. The AIU did not specify the scope of disqualification. Standard practice is automatic annulment of the competition at which the sample was collected, including prize money, plus forfeiture of ranking points accrued after that date. That silence is not a small omission: for a road racer, appearance fee and prize money from that race can cost more than two years of suspension. And what survives should be stated plainly. Results before March are not automatically erased, because the statement records no finding of earlier use. The 2026 Tokyo title and the three Major second places remain in the record book. I spent one night with the 2026 Tokyo splits, checking where the second-half decay began. The runner on that sheet was a solid, disciplined 2:18 to 2:20 marathoner. That runner is now 32 and will next be eligible at 38. Ethiopia's current depth is such that a 2:18 performer is not automatically selectable. Six years is a ban on paper and a career ending in practice. Now the uncomfortable part. Two readings of this case are circulating. The first says the AIU has hardened, four years for a forged document with no softening. The second says the outcome is disproportionate: six years for a substance with no established endurance benefit, legal out of competition. I did not want to run this audit. The audit did not care. My reading is a third one, and it is less comfortable. The enforcement frontier has moved from detection to document verification. In this file the sanction was driven by the paperwork, not the drug. The second layer is that the statement names only the family member. No agent, no manager, no coach who proposed or accepted the prescription. Injured distance runners face pressure to protect appearance-fee income, glucocorticoids are the cheapest and most available tool, and the surrounding medical structure is informal. The forgery is a symptom of an absent system, not the cause. The investigation that reached the prescription never established who asked for it. The media then turned this into a steroid story, and the comparison collapsed. Filing a glucocorticoid case on the anabolic shelf is the same carelessness as keeping the 2026 relay golds on the books without a footnote. Remove the context and what remains is not a number. It is a mood. Three things to watch, and all three will either appear in the documents or fail to. First, whether the reasoned decision states the annulment of the March result and its prize money; that sentence is where the money sits. Second, whether an appeal is filed at CAS; the window is typically about 21 days from the reasoned decision, and a document-based finding is hard to overturn. Third, and most important, what the next road-racing file rests on: a sample or a prescription. If the answer is a prescription, this is not an outlier. It is a category.